OasisLMS

Management of N2 NSCLC - A Case Based Discussion

Perspectives for Lung Cancer Early Detection

IASLC Lectureship Award Session

Early Stage Lung Cancer: Questions and Controversies

Improving Outcomes for Patients with Lung Cancer

Lung Cancer Screening - Next Step

Novel Approaches with IO

Improving Outcomes in Locoregional NSCLC II

PDL1, TMB and DNA Repair

Towards Survivorship: The Landscape, Supports and Barriers

Clinical Trials in Brain Metastases

Lung Cancer Surgical and Molecular Pathology

Considerations in Immunotherapy / Real World

Biomarkers of IO Response

Mesothelioma Surgery and Novel Targets for Prognosis and Therapy

Interventional Pulmonology

Survivorship, Socioeconomic and End-of-Life Considerations

Colliding Approaches - EGFR and Immunotherapy

Novel Mechanisms for Molecular Profiling

New Methods to Improve Lung Cancer Patients Outcomes

Modelling, Decision-Making and Population-Based Outcomes

Genomic Markers of IO Response

Implementation of Lung Cancer Screening

Molecular Subtyping, CBL3, and Non Coding RNA

New Therapeutics, Pathology, and Brain Metastases for Small Cell and Neuroendocrine Tumour

Early Stage Lung Cancer: Present and Future

Genomic Evolution, KEAP 3 and More Non-Coding RNA

Oligometastasis: Defining, Treating, and Evaluating

New Therapies and Emerging Data in ALK, EGFR and ROS1

Novel Drugs and PDX Models

Cancer Pathways, Targeted Therapy and Resistance

The Future of IO

New Frontiers in Oligometastases

Joint GLCC/IASLC Session: Exploring Hot Topics for Advocates

Diagnostic Dilemma in Lung Cancer

Practical Issues in the Management of Oligometastatic NSCLC

Antibody-Drug Conjugates in Advanced NSCLC

Lung Cancer in the Real World

Tumour Board - Tissue Acquisition and Staging

Part Solid Nodules, GGN and STAS

Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control

Immunotherapy and RT

Novel Mediators of Lung Cancer Metastasis

IO in Early Stage NSCLC

Disruptive Technology and Lung Cancer Risk

Implementation of Lung Cancer Screening

Life After Lung Cancer: Survivorship

Management of SCLC Patients Not Represented in Clinical Trials

Pulmonary Dilemmas with Immunotherapy

Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC

Giants in Thoracic Oncology

Biology of the Lung and Lung Cancer

What's New in Targeted Therapy?

Global Perspectives on Tobacco Control

Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes

From Textbook to Practice Around the World

Therapeutic Implications of Staging Issues

IO Combinations in Advanced NSCLC

Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers

Modern Day RT in LA NSCLC: Where Is the Evidence?

Clinical Science in Mesothelioma

SCLC - From Benchside to Bedside - Clinical Science Session

Preclinical Models of Lung Cancer

Update on WHO Classification and Staging of Lung Cancer

Clinical Trial Design With Novel Lung Cancer Therapy

Comparison of Various Risk Models

Role of Pneumonectomy in N2 Disease

Symptom Management in Mesothelioma

Management of Pleural Recurrence

Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges

Management of Advanced Wild-Type Lung Cancer in Special Situations

Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous

Biology of Small Cell Lung Cancer

IO in the Real World - High Risk Populations And Patient Support

Clonal Evolution and Targeted Therapy

Nodule Management (Pro Con Debate and Case Presentations)

Who is Too High Risk for a VATS Resection?

What Is Changing in the Management of Pulmonary Neuroendocrine Tumours?

Living with and Beyond Lung Cancer: An Education for Advocates

Case-Based Management of Patients with Inadequate Tissue for Molecular Tests

How I Treat Advanced Stage Thymic Malignancy Patients

Molecular Testing in Small Samples

Can I Treat Brain Metastasis with Immunotherapy?

Incorporation of Smoking Cessation in Clinical Care

Surgical Considerations Following Induction Therapy for Stage IIIA Disease

Multiple Lung Nodules; Resect, Radiate or Watch?

Enhancing the Care of Your Older Adult Population with Lung Cancer

New Paradigms in Symptom Management in Lung Cancer

Controversies in Radiotherapy for SCLC

Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP

Improving Outcomes in Locoregional NSCLC I

Novel Therapies in ROS1, HER2 and EGFR

Advances in Lung Cancer Pathology

Improving Access and Outcomes in Lung Cancer Management

Clinical Trials in IO

Early Stage Lung Cancer: Outcomes and Interventions

Oligometastasis: What Should Be the State-Of-The-Art?

Mesothelioma: Immunotherapy and microRNA for Diagnosis and Treatment

Right Patient, Right Target & Right Drug - Novel Treatments and Research Partnerships

Thymic and Other Thoracic Tumours: Targeted Therapies, Biomarkers and Neo/Adjuvant Radiotherapy

Novel Therapies in MET, RET and BRAF

Therapeutics and Radiation for Small Cell Lung Cancer

Opening Ceremony

Controversies in Mesothelioma

Debate on Local Therapies for Limited Small Cell Lung Cancer? Surgery PRO/CON and BID Radiation PRO/CON

Controversies in Management of Resectable Thymoma

Targeted Therapy for NSCLC

Optimizing Clinical Trial Design in NSCLC

Controversies in Immunobiomarker Testing

The Future of Cytotoxic Chemotherapy in Advanced NSCLC

The Great Oligometastatic Debates

Approaches to Management of Advanced NSCLC

Patients First

Presidential Symposium - Top 5 Abstracts

Call to Action - Challenges Ahead

Take Action - Key Messages from WCLC 2018 and Goals for 2019

IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening

Highlight of the Previous Day Sessions

Highlight of the Previous Day Sessions

Highlight of the Previous Day Sessions

Mesothelioma Workshop

Endoscopic Diagnosis and Staging of Lung Cancer - Interventional Pulmonology Hands-On Workshop

ITONF Workshop: Excellence in Thoracic Oncology Care

Young Investigators Session